Page last updated: 2024-09-04
xylose and ritonavir
xylose has been researched along with ritonavir in 1 studies
Compound Research Comparison
| Studies (xylose) | Trials (xylose) | Recent Studies (post-2010) (xylose) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 7,016 | 78 | 2,365 | 5,419 | 1,291 | 2,772 |
Protein Interaction Comparison
| Protein | Taxonomy | xylose (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Canani, RB; Cirillo, P; Guarino, A; Spagnuolo, MI | 1 |
Other Studies
1 other study(ies) available for xylose and ritonavir
| Article | Year |
|---|---|
Ritonavir combination therapy restores intestinal function in children with advanced HIV disease.
Topics: Adolescent; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Feces; Female; HIV Infections; HIV-1; Humans; Intestinal Absorption; Iron; Male; Proteins; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Time Factors; Xylose | 1999 |